Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31171534 | 0.92 | CTSK (0.38) | USP2SMN1; SMN2CTSKGPR119MEN1 | |
| SCHEMBL21325460 | 0.88 | CYP4F2 (0.43) | USP2SMN1; SMN2CTSKGPR119MEN1 | |
| SCHEMBL7682979 | 0.87 | USP2 (0.40) | USP2SMN1; SMN2CTSKGPR119MEN1 | |
| SCHEMBL15577439 | 0.86 | CTSK (0.38) | USP2SMN1; SMN2CTSKGPR119MEN1 | |
| SCHEMBL10529377 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2CTSKMEN1KMT2A | |
| SCHEMBL28709409 | 0.85 | USP2 (0.43) | USP2SMN1; SMN2CTSKGPR119MEN1 | |
| SCHEMBL2798365 | 0.85 | USP2 (0.43) | USP2SMN1; SMN2CTSKGPR119MEN1 | |
| SCHEMBL6968885 | 0.84 | ALDH1A1 (0.45) | SMN1; SMN2MEN1KMT2AALDH1A1OPRD1 | |
| SCHEMBL21325459 | 0.83 | USP2 (0.41) | USP2SMN1; SMN2CTSKGPR119MEN1 | |
| SCHEMBL29222475 | 0.83 | USP2 (0.41) | USP2SMN1; SMN2CTSKGPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057971-B1 | 1-(BETA-D-GLUCOPYRANOSYL)-1H-INDOLE COMPOUNDS | LILLY CO ELI (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-3057971-A1 | 1 -(BETA-D-GLUCOPYRANOSYL)-1H-INDOLE COMPOUNDS | Eli Lilly and Company (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9145435-B2 | Urea compounds | ELI LILLY AND COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145435-B2 | Urea compounds | ELI LILLY AND COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145435-B2 | Urea compounds | ELI LILLY AND COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2015057953-A1 | 1 -(BETA-D-GLUCOPYRANOSYL)-1H-INDOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111846-A1 | NOVEL UREA COMPOUNDS | ELI LILLY AND COMPANY | 2015-04-23 | — | — | US | disclosed |
| US-20150111846-A1 | NOVEL UREA COMPOUNDS | ELI LILLY AND COMPANY | 2015-04-23 | — | — | US | disclosed |
| WO-2015057953-A1 | 1 -(BETA-D-GLUCOPYRANOSYL)-1H-INDOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111846-A1 | NOVEL UREA COMPOUNDS | ELI LILLY AND COMPANY | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111846-A1 | NOVEL UREA COMPOUNDS | SLC14A1, SLC10A1, UTS2R | USP2 191/4885SMN1; SMN2 2724/4885CTSK 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.